Join to view full profile
6701 Airport Blvd Bldg BMobile, AL 36608
Phone+1 251-625-6896
Fax+1 251-625-6897
Dr. Heller is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
San Antonio Uniformed Services Health Education ConsortiumFellowship, Hematology and Medical Oncology, 2000 - 2003
Keesler Medical CenterResidency, Internal Medicine, 1997 - 2000
Louisiana State University School of Medicine in New OrleansClass of 1997
Certifications & Licensure
LA State Medical License 2023 - 2027
MS State Medical License 2008 - 2027
AL State Medical License 2007 - 2026
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification OncoEMR by Flatiron Health, Flatiron Health, Inc., 2012, 2014, 2016-2017
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
- Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
- Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Publications & Presentations
PubMed
- 90 citationsPhase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromesGuillermo Garcia-Manero, Guillermo Montalban-Bravo, Jesus G. Berdeja, Yasmin Abaza, Elias J. Jabbour
Cancer. 2017-03-15 - Extreme leukocytosis without hematologic malignancy.Kristina E Orio, Brian J Heller, Michael Osswald
Southern Medical Journal. 2002-12-01
Press Mentions
Southern Cancer Center Adds Genetic Cancer Risk Assessment ProgramJuly 25th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
